All In Biotech

Free tool

FAERS Monitor: Rystiggo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761286 or its brand name (Rystiggo, Rozanolixizumab-Noli). Reports on generic versions are filed under their own applications.

Reports

1,166

Serious

838

72% of reports

Hospitalization

400

Death reported

20

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • myasthenia gravis357
  • drug ineffective191
  • headache175
  • diarrhoea131
  • fatigue108
  • nausea94
  • asthenia86
  • dyspnoea80
  • pyrexia65
  • hospitalisation64
  • therapeutic response shortened57
  • vomiting57
  • myasthenia gravis crisis56
  • off label use53
  • dysphagia50

Reports by year received

View as table
YearReports
202341
2024330
2025421
2026374

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,993 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myasthenia gravisSignal357834.1762.9283,255
myasthenia gravis crisisSignal56708.6545.937,398
therapeutic response shortenedSignal5731.124.11,628
dysphagiaSignal509.57.2374
hospitalisationSignal647.55.9358
headacheSignal1755.04.4579
astheniaSignal864.13.4204
diarrhoeaSignal1313.73.1259
pyrexiaSignal653.42.7109
drug ineffectiveSignal1912.62.3201
dyspnoeaSignal802.52.176
fatigueSignal1082.52.1100
vomitingSignal572.21.736
nauseaSignal942.11.858
off label use531.10.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.